Navigation Links
BioCryst Receives Special Protocol Assessment for Fodosine

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the FDA's Special Protocol Assessment (SPA) process for the design of its planned pivotal clinical trial of the oral formulation of the company's lead oncology compound, Fodosine(TM) (forodesine hydrochloride) in patients with cutaneous T-cell lymphoma.

A Special Protocol Assessment is a request for feedback from the FDA that allows a company to receive official evaluation and guidance on the design of pivotal trial protocols. BioCryst requested the formal assessment, late in the first quarter of 2007, because the pivotal trial is intended to form the primary basis of an efficacy claim in the planned new drug application (NDA) for oral Fodosine.

The multicenter, multinational, open-label, single-arm, repeat-dose pivotal trial is expected to initiate enrollment during the third quarter of 2007. The trial will enroll patients with CTCL of Stage IB through Stage IVA who have disease that is persistent, progressive or recurrent during or after treatment with at least three systemic therapies. The study's primary endpoint is to determine the objective response rate, defined as either complete response or partial cutaneous response, achieved with a once-daily oral regimen of Fodosine(TM). Secondary endpoints include assessing the safety and tolerability of extended daily treatment with oral Fodosine(TM), assessment of the time to objective response and the duration of objective response.

"We are pleased to have reached agreement with the FDA in a timely manner. Receipt of this SPA is an important milestone in the development of Fodosine(TM) and a sign of our commitment to deliver on our goals," said Jon P. Stonehouse, Chief Executive Officer of BioCryst. "We would like to thank the FDA for their input and guidance during this SPA process. BioCryst is now well positioned to begin pati ent enrollment during the third quarter."


'"/>




Related medicine news :

1. BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
2. Fifth US Patient Receives Artificial Heart
3. Northfield Labs Receives FDA Comments
4. British MPs Say Prostate Cancer Receives Low Priority in the NHS
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the ... common cancer among men in the U.S. and the third most common cause of cancer ... that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
(Date:6/24/2017)... ... June 24, 2017 , ... The weather is heating ... outdoors. Home and business owners should be aware that the summer months provide more ... fact, mechanical locks and keys can be negatively affected from direct exposure to the ...
(Date:6/23/2017)... ... 23, 2017 , ... By scoring 100% for fiscal management and accountability, the ... online charity evaluator, Charity Navigator, validating ANRF's work as a top charity in America. ... Charity Navigator and earns ANRF a spot on their “ 10 Charities Worth Watching ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. ... has recently begun offering three new minimally invasive procedures to patients who want ... reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet ...
(Date:6/23/2017)... ... ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique approach to ... technique that he calls the AuraLyft Facelift. The AuraLyft does more than ... expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique approach stems ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... and INDIANAPOLIS , June 9, ... living with diabetes. In a further effort to help ... affected by this condition, the International Diabetes Federation (IDF) ... ) have come together for the second phase of ... Systems programme (BRIDGES 2), reaffirming their commitment to helping ...
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/2/2017)... LAWRENCE, Mass. , June 2, 2017  NxStage ... advancing renal care, today announced new findings demonstrating positive ... NxStage ® System One™. The data will be ... 2017, in Madrid, Spain . ... Knowledge to Improve Home Dialysis Network in ...
Breaking Medicine Technology: